Walgreens Boots Alliance, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US9314271084
USD
11.98
0.06 (0.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Walgreens Boots Alliance, Inc. stock-summary
stock-summary
Walgreens Boots Alliance, Inc.
Pharmaceuticals & Biotechnology
Walgreens Boots Alliance, Inc., is a holding company. The Company is a pharmacy-led health and wellbeing company. The Company operates through three segments: Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Retail Pharmacy USA segment consists of the Walgreen Co. (Walgreens) business, which includes the operation of retail drugstores, care clinics and providing specialty pharmacy services. The Retail Pharmacy International segment consists primarily of the Alliance Boots pharmacy-led health and beauty stores, optical practices and related contract manufacturing operations. The Pharmaceutical Wholesale segment consists of the Alliance Boots pharmaceutical wholesaling and distribution businesses. The Company's portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as global health and beauty product brands, including No7, Botanics, Liz Earle and Soap & Glory.
Company Coordinates stock-summary
Company Details
108 Wilmot Rd , DEERFIELD IL : 60015-5145
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 137 Schemes (37.43%)

Foreign Institutions

Held by 358 Foreign Institutions (13.55%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Skinner
Executive Chairman of the Board
Mr. Stefano Pessina
Executive Vice Chairman of the Board, Chief Executive Officer
Mr. William Foote
Lead Independent Director
Mr. Jose Almeida
Independent Director
Ms. Janice Babiak
Independent Director
Dr. David Brailer
Independent Director
Ms. Ginger Graham
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
38,986 Million
(Quarterly Results - May 2025)
Net Profit:
-196 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,353 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

9,756.20%

stock-summary
Debt Equity

1.26

stock-summary
Return on Equity

-10.20%

stock-summary
Price to Book

1.44